Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenx	$576.24 -0.6%	$587.69	$359.37 ▼ $678.21	$35.19B	0.57	325,666 shs	230,594 shs
ONC Beigene	$240.41 +0.9%	$240.37	$141.31 ▼ $287.88	$23.81B	0.35	462,101 shs	189,191 shs
RDY Dr. Reddy's Laboratories	$14.58 -1.2%	$13.64	$12.26 ▼ $16.89	$12.17B	0.33	1.49 million shs	948,927 shs
TAK Takeda Pharmaceutical	$14.59 -0.5%	$14.67	$12.58 ▼ $15.43	$46.42B	0.26	1.93 million shs	1.39 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenx	-1.33%	+0.25%	-5.69%	-6.94%	+57.95%
ONC Beigene	-1.29%	+0.61%	-2.69%	-7.99%	+23,830,999,900.00%
RDY Dr. Reddy's Laboratories	+2.43%	+1.73%	+6.66%	+13.05%	+5.93%
TAK Takeda Pharmaceutical	+0.72%	+3.09%	-2.33%	+2.30%	+11.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenx	3.3643 of 5 stars	3.5	2.0	0.0	4.2	1.7	1.9
ONC Beigene	2.85 of 5 stars	4.5	0.0	0.0	1.8	1.7	0.6
RDY Dr. Reddy's Laboratories	1.9844 of 5 stars	2.3	2.0	1.7	2.9	0.0	1.9
TAK Takeda Pharmaceutical	2.7591 of 5 stars	0.0	3.0	2.5	3.5	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenx	3.05	Buy	$709.18	23.07% Upside
ONC Beigene	3.00	Buy	$319.00	32.69% Upside
RDY Dr. Reddy's Laboratories	2.50	Moderate Buy	$17.00	16.60% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest RDY, TAK, ARGX, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	ARGX argenx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$699.00
5/14/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/13/2025	ARGX argenx	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/13/2025	ARGX argenx	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$680.00 ➝ $680.00
5/9/2025	ARGX argenx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$704.00 ➝ $708.00
5/9/2025	ARGX argenx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,100.00 ➝ $1,065.00
5/9/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$796.00 ➝ $803.00
5/8/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
4/28/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$312.00 ➝ $312.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenx	$2.58B	13.64	N/A	N/A	$69.22 per share	8.32
ONC Beigene	$4.18B	5.70	N/A	N/A	$37.10 per share	6.48
RDY Dr. Reddy's Laboratories	$325.54B	0.04	$1.10 per share	13.25	$4.50 per share	3.24
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.42 per share	4.27	$15.39 per share	0.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenx	-$295.05M	$16.21	N/A	53.11	N/A	-2.11%	-1.45%	-1.29%	7/24/2025 (Estimated)
ONC Beigene	-$881.71M	-$3.72	N/A	338.61	7.73	-25.94%	-25.12%	-14.95%	N/A
RDY Dr. Reddy's Laboratories	$668M	$0.66	23.22	17.78	N/A	17.25%	17.87%	12.32%	7/25/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.22	36.48	8.84	0.24	4.53%	9.39%	4.53%	7/30/2025 (Estimated)

Latest RDY, TAK, ARGX, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	$0.22	+$0.02	$0.22	$83.70 billion	$996.17 million
5/8/2025	Q1 2025	ARGX argenx	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/7/2025	Q1 2025	ONC Beigene	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenx	N/A	N/A	N/A	N/A	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.08	0.55%	N/A	12.12%	N/A
TAK Takeda Pharmaceutical	$0.53	3.63%	-8.36%	240.91%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenx	N/A	8.53	7.88
ONC Beigene	0.05	1.93	1.72
RDY Dr. Reddy's Laboratories	0.02	1.92	1.38
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenx	60.32%
ONC Beigene	48.55%
RDY Dr. Reddy's Laboratories	3.85%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenx	2.43%
ONC Beigene	6.62%
RDY Dr. Reddy's Laboratories	2.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenx	650	61.06 million	59.29 million	Optionable
ONC Beigene	9,000	99.05 million	90.59 million	N/A
RDY Dr. Reddy's Laboratories	24,800	834.77 million	818.05 million	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

RDY, TAK, ARGX, and ONC Headlines

Recent News About These Companies

Voloridge Investment Management LLC Raises Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 28 at 4:47 AM | marketbeat.com

Forum Financial Management LP Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 27 at 5:36 AM | marketbeat.com

GTS Securities LLC Makes New Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 27 at 5:05 AM | marketbeat.com

26,600 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Point72 Asset Management L.P.

May 26 at 4:07 AM | marketbeat.com

510,600 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Acquired by Toronto Dominion Bank

May 24, 2025 | marketbeat.com

First AI-generated drugs may reach market by 2030: Insilico CEO

May 23, 2025 | moneyweb.co.za

First AI-generated drugs could go on sale by 2030

May 22, 2025 | techcentral.co.za

Millennium Management LLC Sells 1,655,703 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 22, 2025 | marketbeat.com

Janus Henderson Group PLC Has $3.10 Million Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 22, 2025 | marketbeat.com

Soleus Capital Management L.P. Purchases 680,000 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 21, 2025 | marketbeat.com

Focus Partners Wealth Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 20, 2025 | marketbeat.com

Quantinno Capital Management LP Increases Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 19, 2025 | marketbeat.com

Dimensional Fund Advisors LP Increases Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 17, 2025 | marketbeat.com

230,000 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Purchased by LMR Partners LLP

May 15, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Holdings Raised by Hudson Bay Capital Management LP

May 15, 2025 | marketbeat.com

Balyasny Asset Management L.P. Invests $2.56 Million in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 15, 2025 | marketbeat.com

BNP Paribas Financial Markets Has $6.63 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 15, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Stake Increased by Jane Street Group LLC

May 15, 2025 | marketbeat.com

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

May 14, 2025 | businesswire.com

Takeda Pharmaceutical (NYSE:TAK) Shares Gap Down - Should You Sell?

May 14, 2025 | marketbeat.com

Ethic Inc. Sells 113,512 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?
By Leo Miller | May 20, 2025
View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?
Aerospace and Defense Stocks Take Flight After Strong Earnings
By Leo Miller | April 29, 2025
View Aerospace and Defense Stocks Take Flight After Strong Earnings
5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears
By Thomas Hughes | May 14, 2025
View 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears
Is Intel Stock a Bargain or a Burden? Cheap Stock, High Stakes
By Jeffrey Neal Johnson | May 7, 2025
View Is Intel Stock a Bargain or a Burden? Cheap Stock, High Stakes
Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
By Nathan Reiff | May 10, 2025
View Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?

RDY, TAK, ARGX, and ONC Company Descriptions

argenx NASDAQ:ARGX

$576.24 -3.53 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$575.45 -0.79 (-0.14%)

As of 07:02 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Beigene NASDAQ:ONC

$240.41 +2.10 (+0.88%)

As of 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Dr. Reddy's Laboratories NYSE:RDY

$14.58 -0.17 (-1.15%)

Closing price 03:59 PM Eastern

Extended Trading

$14.56 -0.02 (-0.10%)

As of 04:57 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Takeda Pharmaceutical NYSE:TAK

$14.59 -0.08 (-0.55%)

Closing price 03:59 PM Eastern

Extended Trading

$14.58 -0.02 (-0.10%)

As of 07:17 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time